The Price of Our Medicines
Amgen's commitment to innovation has led us to launch groundbreaking therapies to treat serious illnesses. To ensure we meet the needs of patients who can benefit from our medicines worldwide, Amgen is committed to producing safe and effective therapies that can be appropriately accessed by the patients who need them most.
We follow a core set of principles for responsible pricing across the world, including developing countries, which include the following considerations:
- Reflects the economic value to society generated through improvement in life expectancy or reduction in risk of disease- or-treatment-related complications
- Reflects the clinical benefits and any medical costs avoided, and broader value to patients, caregivers and payers
- Enables access to medicines for appropriate patients
- Recognizes the local healthcare infrastructure and elements of the product supply chain as well as the competitive landscape of each country
- Enables continued investment to fund scientific innovation
In our efforts to balance local economic constraints and appropriate access to innovative therapies we may employ price policies that vary within regions and even within a given country. Price policies for Amgen products take into account a number of important factors in each country, including but not limited to:
- Cost-effectiveness thresholds
- Budget impact in countries offering National Healthcare / Socialized Medicine
- Patient ability to pay
- Per-Capita Gross Domestic Product (GDP)
- Healthcare spending as a proportion of GDP
While our product pricing aims to ensure patient access, in some countries adaptive pricing alone may not guarantee access to our medicines. Other elements and activities beyond Amgen's control such as healthcare infrastructure, supply chain / distribution structure, and public health funding priorities may impact access and affordability of Amgen products for patients who can benefit from our medicines.